Authors

• Giovanni Melillo
• Michael J. Paskow (ORCID: https://orcid.org/0000-0001-8850-9044)
• Heide A. Stirnadel-Farrant (ORCID: https://orcid.org/0000-0003-0734-0422)
• Janvi Sah (ORCID: https://orcid.org/0000-0002-7856-5947)
• Mufiza Farid‐Kapadia (ORCID: https://orcid.org/0000-0001-8242-2343)
• Marcus-Alexander Wörns
• Jennifer J. Knox (ORCID: https://orcid.org/0000-0003-3474-6647)
• Chiun Hsu (ORCID: https://orcid.org/0000-0002-1122-0055)
• Mehmet Akce (ORCID: https://orcid.org/0000-0003-4747-7722)
• Niall C. Tebbutt (ORCID: https://orcid.org/0000-0003-2613-5168)
• Andrea Casadei‐Gardini (ORCID: https://orcid.org/0000-0001-6289-7202)
• Joanna Schmidt
• Masafumi Ikeda
• Boris Baur
• Anna Daktera

Institutions

• AstraZeneca (United Kingdom) (GB)
• Vita-Salute San Raffaele University (IT)
• Witten/Herdecke University (DE)
• National Taiwan University (TW)
• University of Toronto (CA)
• Princess Margaret Cancer Centre (CA)
• University of Alabama at Birmingham (US)
• AstraZeneca (Brazil) (BR)
• Klinikum Dortmund (DE)
• National Taiwan University Hospital (TW)
• National Cancer Center Hospital East (JP)
• AstraZeneca (Canada) (CA)
• AstraZeneca (United States) (US)
• Olivia Newton-John Cancer Wellness & Research Centre (AU)
• Austin Health (AU)

Publication Details

Journal

Future Oncology

Published

2025-11-24

DOI

https://doi.org/10.1080/14796694.2025.2589057

Primary Topic

Cholangiocarcinoma and Gallbladder Cancer Studies

Type

article

Field-Weighted Citation Impact

0.00